Prot #391402: A Phase 1/2a, Open-Label, Parallel, Two-Arm Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects with Refractory Ovarian Cancer with Malignant Ascites

Project: Research project

Project Details

StatusFinished
Effective start/end date3/17/16 → 3/17/19

Funding

  • Quintiles, Inc. (Prot #391402)
  • Baxalta US Inc. (Prot #391402)